Insight, China's Pharmaceutical Industry

Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that China’s National Medical Products Administration (NMPA) has granted...

Company Deals

Gilead Exercises Option on Kymera’s KT-200 for $45M – Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies

Fineline Cube Apr 12, 2026

Kymera Therapeutics, Inc. (NASDAQ: KYMR) announced that partner Gilead Sciences Inc. (NASDAQ: GILD) has exercised its exclusive...

Company Drug

Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer – Multi‑Target TKI Advances in 2L+ ESCC

Fineline Cube Apr 12, 2026

Konruns Pharmaceutical Co., Ltd (SHA: 603590) announced that China’s National Medical Products Administration (NMPA) has approved...

Company Deals

Sinocelltech to Raise RMB 900M via Private Placement – Funds Working Capital for Biologics Pipeline

Fineline Cube Apr 12, 2026

Sinocelltech Group Ltd (SHA: 688520) announced plans to raise up to RMB 900 million (US$132 million) through a...

Company Deals

NorrDia Medical Raises RMB 100M+ to Complete Bellco Acquisition – Builds Global Blood Purification Platform

Fineline Cube Apr 12, 2026

NorrDia Medical, a Ningbo‑based blood purification specialist, announced completion of a RMB 100 million+ (US$14.6 million) financing...

Company Deals

Vivatides Therapeutics Closes $54M Series A to Advance Extrahepatic Oligonucleotide Delivery Platform – Led by Qiming Venture Partners

Fineline Cube Apr 12, 2026

Vivatides Therapeutics announced the completion of an oversubscribed USD 54 million Series A financing round,...

Company Deals

C4 Therapeutics and Roche Forge $1B+ DAC Collaboration to Pioneer Degrader-Antibody Conjugates in Oncology

Fineline Cube Apr 10, 2026

C4 Therapeutics, Inc. (NASDAQ: CCCC), a leader in targeted protein degradation (TPD), announced an expanded...

Company Drug

Lynk Pharmaceuticals’ JAK1 Inhibitor Zemprocitinib Enters NMPA Review for Atopic Dermatitis

Fineline Cube Apr 10, 2026

Lynk Pharmaceuticals Co., Ltd., a clinical-stage Chinese biopharmaceutical company, announced that the National Medical Products...

Company Deals

Thermo Fisher Scientific Partners with Singapore’s PRECISE to Power Landmark Proteomics Study PRECISE-SG100K

Fineline Cube Apr 10, 2026

Thermo Fisher Scientific Inc. (NYSE: TMO), the global life sciences leader, announced a strategic collaboration...

Company Drug

Shanghai Ark Bio Advances AK0406, a Next-Gen Long-Acting Influenza ADFC, into Phase I Trial in Australia

Fineline Cube Apr 10, 2026

Shanghai Ark Biopharmaceutical Co., Ltd., a China-based clinical-stage biotech, announced that its investigational long-acting antiviral...

Company Drug

BeOne Medicines Secures NMPA Conditional Approval for Imdelltra (Tarlatamab) in Heavily Pretreated Small Cell Lung Cancer

Fineline Cube Apr 10, 2026

BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that China’s National...

Company Deals

Oricell Therapeutics Secures $110M+ Pre-IPO Round to Advance First-in-Class CAR-T for Liver Cancer

Fineline Cube Apr 10, 2026

Oricell Therapeutics Co., Ltd., a clinical-stage Chinese biotech developing next-generation CAR-T therapies, announced it has...

Company Drug

Duality Biologics’ HER2-Targeted ADC DB-1303 (BNT323) Enters NMPA Review for Metastatic Breast Cancer

Fineline Cube Apr 10, 2026

Duality Biologics Co., Ltd. (HKG: 9606), a U.S.-China biotech specializing in antibody-drug conjugates (ADCs), announced...

Company Deals

IntuitiveFosun Partners with Sinopharm CDMC to Advance Surgical Robotics Adoption in China

Fineline Cube Apr 10, 2026

IntuitiveFosun, the China-focused joint venture between Intuitive Surgical, Inc. (NASDAQ: ISRG) and Shanghai Fosun Pharmaceutical...

Company Drug

Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China

Fineline Cube Apr 9, 2026

Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that its novel drug candidate HSK42360 has been...

Company Drug

Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia

Fineline Cube Apr 9, 2026

Luye Pharma Group (HKG: 2186) announced first patient enrollment in a Phase II clinical study evaluating...

Company Drug

Sino Biopharm Wins FDA Approval for Pan‑KRAS Inhibitor TQB3205 – First‑in‑Human Trial in Advanced Malignancies

Fineline Cube Apr 9, 2026

Sino Biopharmaceutical Ltd (HKG: 1177) announced that the US Food and Drug Administration (FDA) has granted...

Company Drug

GenFleet Therapeutics Secures First‑Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer

Fineline Cube Apr 9, 2026

GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) announced that China’s National Medical Products Administration (NMPA) has granted...

Company Deals

Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea

Fineline Cube Apr 9, 2026

Gan & Lee Pharmaceuticals (SHA: 603087) announced a licensing agreement with JW Pharmaceutical, granting the South...

Company Deals

Grand Pharma Partners with HKU on Anti‑Infective Drug Discovery – Exclusive License Deal Targets Novel Antibacterial Therapies

Fineline Cube Apr 9, 2026

Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced a strategic partnership with The University of Hong...

Insight, China's Pharmaceutical Industry

Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Shaanxi Micot Enrolls First Patient in Phase Ib/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment

Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies

Gilead Exercises Option on Kymera’s KT-200 for $45M – Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies

Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer – Multi‑Target TKI Advances in 2L+ ESCC

Sinocelltech to Raise RMB 900M via Private Placement – Funds Working Capital for Biologics Pipeline

NorrDia Medical Raises RMB 100M+ to Complete Bellco Acquisition – Builds Global Blood Purification Platform

Vivatides Therapeutics Closes $54M Series A to Advance Extrahepatic Oligonucleotide Delivery Platform – Led by Qiming Venture Partners

C4 Therapeutics and Roche Forge $1B+ DAC Collaboration to Pioneer Degrader-Antibody Conjugates in Oncology

Lynk Pharmaceuticals’ JAK1 Inhibitor Zemprocitinib Enters NMPA Review for Atopic Dermatitis

Thermo Fisher Scientific Partners with Singapore’s PRECISE to Power Landmark Proteomics Study PRECISE-SG100K

Shanghai Ark Bio Advances AK0406, a Next-Gen Long-Acting Influenza ADFC, into Phase I Trial in Australia

BeOne Medicines Secures NMPA Conditional Approval for Imdelltra (Tarlatamab) in Heavily Pretreated Small Cell Lung Cancer

Oricell Therapeutics Secures $110M+ Pre-IPO Round to Advance First-in-Class CAR-T for Liver Cancer

Duality Biologics’ HER2-Targeted ADC DB-1303 (BNT323) Enters NMPA Review for Metastatic Breast Cancer

IntuitiveFosun Partners with Sinopharm CDMC to Advance Surgical Robotics Adoption in China

Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China

Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia

Sino Biopharm Wins FDA Approval for Pan‑KRAS Inhibitor TQB3205 – First‑in‑Human Trial in Advanced Malignancies

GenFleet Therapeutics Secures First‑Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer

Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea

Grand Pharma Partners with HKU on Anti‑Infective Drug Discovery – Exclusive License Deal Targets Novel Antibacterial Therapies

You Missed

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Shaanxi Micot Enrolls First Patient in Phase Ib/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment

China’s NMPA Unveils Comprehensive Regulatory Framework for Cell and Gene Therapy Products with Streamlined Review Pathways

Changchun High & New Tech Secures NMPA Clinical Approval for GenSci164 PTH1R Agonist in Hypoparathyroidism Treatment